/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Altimmune Inc share price today is $3.6492, up -5.26%. The stock opened at $3.77 against the previous close of $3.8, with an intraday high of $3.77 and low of $3.58.

style

pb-0

Altimmune Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$3.6492 -0.0526(-5.26%) ALT at 13 Mar 2026 11:57 AM Biotechnology

Lowest Today 3.58

Highest Today 3.77

Today’s Open 3.77

Prev. Close 3.8

52 Week High 7.73

52 Week Low 2.90

Day’s Range: Low 3.58 High 3.77

52-Week Range: Low 2.90 High 7.73

Altimmune Inc Institutional Holdings

Altimmune Inc Market Status

Strong Buy: 5

Buy: 3

Hold: 1

Sell: 0

Strong Sell: 0

Altimmune Inc Fundamentals

Market Cap 475.88 M

PB Ratio 2.116

PE Ratio 0.0

Enterprise Value 238.11 M

Total Assets 279.93 M

Volume 2959387

Altimmune Inc Company Financials

Annual Revenue FY23:279000 0.3M, FY22:-68000 -0.1M, FY21:4410356 4.4M, FY20:8185027 8.2M, FY19:5801401 5.8M

Annual Profit FY23:null 0.0M, FY22:-68000 -0.1M, FY21:4410356 4.4M, FY20:8185027 8.2M, FY19:5801401 5.8M

Annual Net worth FY23:-78466000 -78.5M, FY22:-84713000 -84.7M, FY21:-96171311 -96.2M, FY20:-49044477 -49.0M, FY19:-20520131 -20.5M

Quarterly Revenue Q3/2025:5000 0.0M, Q2/2025:5000 0.0M, Q1/2025:5000 0.0M, Q3/2024:5000 0.0M, Q2/2024:5000 0.0M

Quarterly Profit Q3/2025:-14955000 -15.0M, Q2/2025:5000 0.0M, Q1/2025:5000 0.0M, Q3/2024:5000 0.0M, Q2/2024:-56000 -0.1M

Quarterly Net worth Q3/2025:-19014000 -19.0M, Q2/2025:-22146000 -22.1M, Q1/2025:-19575000 -19.6M, Q3/2024:-22845000 -22.8M, Q2/2024:-24640000 -24.6M

About Altimmune Inc & investment objective

Company Information Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Organisation Biotechnology

Employees 57

Industry Biotechnology

CEO Mr. Jerome Benedict Durso

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*